Clinical Trials

46 enrolled 19 charts

Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Gynecologic

Ovarian Neoplasms

NCT04393285 2026-03-09

Abemaciclib and Letrozole to Treat Endometrial Cancer

53 enrolled

Gynecologic

Endometrial Neoplasms

NCT03531645 2026-03-05

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

18 enrolled

Other neoplasm

Malignant Neoplasms of Female Genital Organs

NCT05307705 2026-03-02

PIKASSO-01

193 enrolled

Breast Neoplasms

NCT05413304 2026-02-27

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

1 enrolled

CNS

Brain Neoplasms, Glioma

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT04751929 2026-02-20

Abemaciclib With or Without Atezolizumab for mCRPC

19 enrolled 13 charts

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

37 enrolled

Breast Neoplasms

NCT02152631 2026-02-06

JUNIPER

453 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT02779751 2026-01-26

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

100 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

EndocrineGastrointestinalNET

20 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

46 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04010357 2025-12-02

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

14 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Phase EARLY_PHASE1 Active not recruiting

Breast Neoplasms

NCT03837821 2025-11-18

CLONEVO

20 enrolled

Urinary Bladder Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT03939897 2025-09-24

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

24 enrolled 15 charts

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02981940 2025-09-02

A Study of Abemaciclib in Recurrent Glioblastoma

45 enrolled 10 charts

CNS

Brain Neoplasms, Glioblastoma

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

BreastClassical hematology

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT02846987 2025-06-05

Study of Abemaciclib in Dedifferentiated Liposarcoma

33 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT04188548 2025-06-04

EMBER

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03155997 2025-04-20

monarchE

5,637 enrolled 12 charts 2 FDA

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT03969706 2024-11-18

Abemaciclib in Patients with Oligodendroglioma

10 enrolled

CNS

Oligodendroglioma

NCT04545710 2024-08-05

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance